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Abstract
Chronic migraines are a common debilitating headache disorder. Recently, there has 
been increasing interest in the use of onabotulinumtoxinA as a preventative treatment, 
as studies have shown significant benefits. In line with current accepted theories on the 
pathophysiology of migraines, the toxin works by both direct and indirect means to pre-
vent peripheral and central nerve sensitization. While efficacy has been established, the 
technique for extracranial delivery of onabotulinumtoxinA continues to see changes in 
an effort to seek better outcomes. The PREEMPT injection protocol is the original injec-
tion paradigm design targeting broad muscle groups. The ART injection paradigm 
offers the ability to deliver onabotulinumtoxinA closer to culprit nerves, thus increasing 
its effect and also decreasing adverse effects. OnabotulinumtoxinA is an effective and 
 well-tolerated option for selective patients seeking relief from migraine headaches.
Keywords: BTX, onabotulinum toxin, migraine, ART, PREEMPT, trigger site theory
1. Introduction
Chronic migraines are the most common type of headache in patients that seek treatment, 
according to the data compiled from several specialty headache centers in the United States 
[1–3]. It is a debilitating disorder that not only has the ability to severely reduce the quality of 
life, but also causes a heavy economic burden. However, among the high number of patients 
that suffer from chronic migraines, only a third receive prophylactic treatments [4].
Over the last couple of decades, there has been an increasing interest in the use of onabotu-
linumtoxinA (BTX-A) as a preventative treatment for migraine headaches. Over time, a number 
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of well-designed large-scale studies demonstrated that this neurotoxin to be effective in reduc-
ing several measures of migraine symptomology [5–11]. The first major landmark study, called 
the PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy) trials, indicated 
that BTX-A is indeed effective and safe in treating migraine headaches. These studies showed a 
statistically significant reduction in the primary endpoint of headache day frequency in chronic 
migraine patients. They also demonstrated significant reductions in several other measures of 
migraine symptomology such as cumulative hours of headaches, headache days, and days of 
moderate/severe headaches [9]. Further studies indicated efficacy in reducing disease burden 
based on patient quality of life questionnaires [10, 11]. However, studies evaluating the effect 
of BTX-A on episodic migraines so far have not shown significant benefits [12–15]. This led 
to BTX-A being approved by the Food and Drug Administration (FDA) for the treatment of 
chronic migraine headaches. The injection paradigm used in the PREEMPT trails was designed 
based on the initial injection sites reported in earlier phase II trials [16, 17]. While the PREEMPT 
injection protocol is proven to be effective, research is ongoing with several other BTX-A injec-
tion techniques that have been developed. One in particular is the targeted approach, which 
was first done to pre-screen surgical decompression and later developed into a more formal 
technique used solely for preventative treatment purposes.
Currently, BTX-A is used to provide safe and effective long-term treatment for chronic 
migraine headaches. To appreciate the differences and advantages in BTX-A injection tech-
niques between the two specialties, it is important to understand the different targets of injec-
tion, the trigger point and nerve compression hypothesis, mechanism of action of BTX-A in 
the treatment of migraines, and the anatomy of various muscles and nerves has only recently 
been elucidated by studies done between Cleveland and Dallas [6, 7, 18–20]. In this chapter, 
we discuss the PREEMPT injection paradigm and the Anatomical Regional Targeted (ART) 
BTX-A paradigm.
2. Mechanism of onabotulinumtoxinA
OnabotulinumtoxinA, one of the seven serotypes secreted by the Clostridium botulinum bacte-
ria, is currently approved for use in several conditions including strabismus, blepharospasm, 
cervical dystonia, and glabellar lines. Only serotypes A and B are used in the medical context. 
The toxin works by blocking various activities at neuron junctions that depend on intracel-
lular vesicle trafficking to the membrane, such as neurotransmitter release [21, 22]. Normally, 
stored acetylcholine is transmitted via intracellular vesicles that fuse at the surface outer mem-
brane. OnabotulinumtoxinA cleaves the SNAP-25 protein at the surface membrane, inhibiting 
the SNARE complex system of vesicular fusion and thus preventing subsequent neurotrans-
mitter release into the nerve junction [23]. In the context of pure cosmetic treatments, this 
mechanism inhibits contractions of superficial musculature on the face, eliminating the fold-
ing of skin. In the context of migraine treatment, the toxin likely works by inhibiting both 
motor and sensory neurons. Similar to cosmetic treatment, motor neuron inhibition is ben-
eficial to the migraine patient. If nerve irritation is caused by impingement from an overac-
tive muscle, the myorelaxant effect would reduce this irritation. On the other hand, another 
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mechanism of migraine headaches genesis is hypersensitivity of sensory neurons, specifically 
nociceptor neurons. BTX-A acts as a direct analgesic by blocking these hyperexcitable nocicep-
tors. Studies have shown that BTX-A blocks the release of a number of nociceptive mediators, 
preventing the hypersensitization of peripheral nociceptors [24]. By blocking peripheral pain 
signaling to the central nervous system, BTX-A thus indirectly blocks central sensitization. 
Additionally, BTX-A has direct effects on nerves. In animal studies, BTX-A has been shown 
to both prevent and reverse sensitization of nociceptors [25]. If given prophylactically, BTX-A 
reduces the increase in spontaneous firing rate caused by later sensitization. It also reduces 
the spontaneous firing rate of already sensitized nociceptors [25]. Due to inhibition of the 
SNARE complex, the activity of chemoreceptors (TRPA1 and TRPV1) required for nocicep-
tion is also reduced [26]. Importantly, recent evidence suggests that depositing BTX-A closer 
to nerves increases its effect, versus being distributed within a muscle group [26]. Therefore, 
the toxin's benefit in the prophylactic treatment of chronic migraines is likely due to several 
interacting effects including the inhibition of overactive motor neurons and the prevention/
reversal of nociceptor sensitization [27].
3. Diagnosis of chronic migraines and candidacy for onabotulinumtoxinA
Prior to being treated for migraine headaches by BTX-A injection, it is critical for the patient to 
be seen by a board-certified neurologist, preferably one who specializes in headache medicine. 
If the neurologist does not offer BTX-A injection, collaboration with other specialties such as 
plastic surgery, ENT, or pain management for the injections can be done. A multidisciplinary 
team approach with plastic surgery, neurology, psychiatry, sleep medicine, and pain manage-
ment working in conjunction with each other is an effective and preferred approach. The neu-
rologist should evaluate and confirm the diagnosis of chronic migraine headache, ruling out 
other likely causes of recurring headaches that may not respond to BTX-A injection. Results 
from the PREEMPT part 1 and part 2 trials established BTX-A as safe and effective for chronic 
migraine patients. However, BTX-A should be avoided in patients who have previous hyper-
sensitivity reactions to the toxin. Other contraindications include pre-existing neuromuscular 
disorders (myasthenia gravis and Lambert-Eaton syndrome), peripheral motor neuropathies, 
and amyotrophic lateral sclerosis that can increase the risk of significant side effects. It is 
unclear how effective BTX-A is in treating other commonly seen headache types, such as 
cluster, tension, and episodic headaches, as results have been mixed [15–17, 28–30]. Lastly, 
the majority of insurance carriers in the United States require documentation of migraine and 
headaches days, and previous failure of several classes of migraine medications.
4. Trigger sites and peripheral nerve irritation hypothesis
Because of its complex and multifactorial etiology, the exact pathophysiology of migraine 
headaches has yet to be completely elucidated. There are several commonly accepted theories 
based on central and peripheral mechanisms. In the context of onabotulinumtoxinA injection 
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for migraine headaches, local inflammation sensitizes sensory neurons and upregulates the 
recruitment of sensory nociceptors [31–38]. As alluded to earlier, migraine pathophysiology 
involves irritation of peripheral nerves. Specifically, it involves several branches of the trigem-
inal nerve. Subsequent repeated irritation of the nerve causes an augmented perception of 
pain. The trigger point hypothesis attempts to explain this cycle of inflammation and trigemi-
nal neuronal hypersensitivity. It takes into account that patients are often able to describe the 
origin of their migraine pain in a specific area, and that each site of origin leads to a different 
constellation of symptoms. Among other mechanisms, irritation of extracranial nerves in the 
periphery can be caused by overactivity of surrounding musculature, tight fascial bands, and 
intimate neurovascular relationships. Therefore, irritation of peripheral nerves by adjacent 
muscular contraction or other contact points can cause release of inflammatory factors, trig-
gering the onset of migraine headaches. In this context, onabotulinumtoxinA can be targeted 
to these potential trigger sites in an attempt to prevent or inhibit the inflammatory cycle lead-
ing to peripheral and central sensitization. This theory and its implication in the success or 
failure of migraine surgery should not influence the fact that anatomical knowledge of the 
nerve locations can improve BTX-A injection techniques. Even if some neurologists do not 
hold the peripheral nerve compression theory correct, evidence now shows that BTX-A is 
most effective when deposited closer to nerves, acting by means of either direct reduction 
of chemoreceptors on the nociceptor membrane surface, or indirect decrease in activity by 
reducing mechanosensitivity [25, 26].
Trigger sites are identified by regions where the pain originates, rather than other final loca-
tions where the pain may travel. To assess which sites are active, a Migraine Diary should 
be completed by patients each day for at least 4 weeks. Since patients often do not pay espe-
cially close attention to the exact location where pain begins, this log is very useful in keeping 
track of trigger origin sites. In addition to the migraine diary, a thorough history should be 
obtained to differentiate between sites where pain begins and sites where pain may radiate 
to. Because trigger sites are where the pain originates, injection of targeted BTX-A should 
be focused in these sites and not where the pain ends. However, a more liberal approach to 
targeted injection is to inject all the regions. Currently, there are six major trigger sites rel-
evant to available treatment methods, which can be categorized into several “regions”: frontal 
(Site I), temporal (Site II), rhinogenic (Site III), occipital (Sites IV and VI), and auriculotempo-
ral (Site V). Site I refers to headaches beginning in the lateral and central forehead areas, with 
central and cephalad radiation. Patients often describe the pain beginning above the eye and 
moving from outside to inside. At times, palpation with a single finger at the area of the supra-
orbital and supratrochlear nerve will reveal tender areas where the supraorbital nerve (SON) 
and supratrochlear nerve (STN) are involved. In some cases, hypertrophy of the corrugator 
supercilii muscle may be visible on physical exam. Site II, or the temporal trigger site, is asso-
ciated with headaches originating in the temple. Often times, pain radiates toward the lateral 
temporal and posterior auricular areas. The temporalis muscle may be larger than normal, or 
tighter than usual. However, it is important to differentiate temporomandibular joint (TMJ) 
pathology, as it is not a trigger site for migraine headaches. In this region, the zygomaticotem-
poral branch of the trigeminal nerve (ZTBTN) is involved in the generation of pain. Site III 
refers to pain of nasoseptal origin. This pain is usually associated with weather changes and 
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atmospheric pressure changes, usually beginning in the early hours of the morning. Patients 
may complain of rhinitis, hyposmia, anosmia, halitosis, and dental pain. Because of this, they 
can also complain of breathing problems. In addition, this pain is generally described as start-
ing behind the eye and radiating outward. Oxymetazoline nasal spray is used to temporarily 
abort headaches originating from this site. Of note, septal triggers should be considered if 
pain persists despite BTX-A injection in other trigger sites. To confirm an active trigger site 
in the septal area, imaging via computed tomography scan is required. Intranasal pathology 
such as septal deviation contacting turbinates, concha bullosae, and other masses can be iden-
tified and surgically treated. It is important to rule out septonasal origin, as BTX-A generally 
does not improve pain originating from site III. Site IV occipital trigger site refers to head-
aches originating in the back of the neck and radiating anteriorly. This area usually correlates 
with the anatomical course of the greater occipital nerve (GON). Palpation in this area usu-
ally reveals a point of maximal tenderness that corresponds to the location where the nerve 
pierces the semispinalis capitis muscle. Some injection techniques target the semispinalis and 
splenius capitis, as well as the occipitalis muscle, but generally BTX-A is deposited as close to 
the nerve as possible. Patients may also complain of retroauricular pain associated with this 
site. Of note, it is possible that an intimate neurovascular relationship between the greater 
occipital nerve and occipital artery at this trigger site plays a major role in migraine devel-
opment [6, 18, 20, 39]. The close relationship of the greater occipital nerve with the occipital 
artery can cause pain to fluctuate with weather, as arterial vascular tone changes. In general, 
pain in the occipital region mostly involves the GON, while the third occipital nerve (TON) 
may be involved to a lesser degree. Site V refers to pain in the area corresponding to the 
auriculotemporal nerve (AT). Pain in this area is caused by TMJ facial bands inferiorly and the 
temporal artery more superiorly, causing irritation to the AT nerve [40]. Finally, Site VI refers 
to the area around the lesser occipital nerve.
While these areas are the major sites relevant to currently available treatment modalities, 
a number of other sites have been reported to cause significant pain. The trapezius muscle 
group, TMJ muscle group, sternocleidomastoid muscle, and masseter are few examples. 
While patient description should aid in the selection and specific location of injection sites, 
actual injection is based on the anatomy of the culprit nerves and surrounding tissue.
5. Techniques for injection
5.1. PREEMPT injection paradigm [24]
The injection protocol used in the phase III PREEMPT trials were based on, and developed 
upon, earlier phase II studies that demonstrated safety and efficacy in the use of onabotuli-
num toxin for chronic migraine patients. Using this PREEMPT injection paradigm, the phase 
III part 1 and part 2 studies confirmed significant reduction in the frequency of headache days 
and low rates of adverse events [9, 41]. At 24 weeks, pooled data from both trials reported a 
significant difference in the reduction of headache days compared to placebo. Specifically, 
those who underwent 24 weeks of BTX-A injection had a 7.4 day reduction, while placebo 
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had a 4.7 reduction in headache days [10]. Thus, the PREEMPT injection protocol is a proven 
prophylactic treatment for chronic migraine patients.
As the first formal injection protocol described, the PREEMPT technique is a combination of a 
“fixed site” and “follow the pain” approaches. This was based on a number of earlier studies 
employing different approaches. From these studies, this combination approach was deter-
mined as the most optimal protocol to be used in the PREEMPT trials [24]. A total of 155 units 
are injected into 31 fixed sites, targeting a number of muscle groups. In addition to these fixed 
site and fixed dose (FSFD) sites, an additional eight sites and 40 units can be injected accord-
ing to physician discernment in a “follow the pain” approach. Therefore, the PREEMPT injec-
tion paradigm uses a minimum of 155 units and a maximum of 195 units, which corresponds 
well with the determined optimal dosage range between 150 and 200 units [24]. Figure 1 
shows the PREEMPT injection protocol in each area. A standard 30-gauge 0.5-inch syringe is 
used, and an injection interval of 12 weeks is followed.
5.1.1. Frontal
In the frontal region, a total of 35 units are injected in a shallow manner into four muscle 
groups. First, the corrugator muscle is injected bilaterally 1.5 cm above the medial superior 
edge of the orbital ridge, with 10 units into each side. In the midline, the procerus is injected 
with 5 units in a location midway between the two corrugator injections. Finally, injection of 
the frontalis is divided into four sites, with 20 units total. On one side, the medial injection is 
1.5 cm above the corrugator injection, and the lateral injection is 1.5 cm away from the medial 
injection in the same horizontal plane. This is repeated on the opposite side of the forehead.
5.1.2. Temporal
In the temporal region, the temporalis muscle is the main muscle group targeted. Injection in 
this area consists of four sites on each side of the head. A total of 20 units are injected into each 
side. The first injection is behind the anterior border of the temporalis muscle. The second injec-
tion is 0.5 cm above and 1.5 cm posterior to the first injection. The third and fourth injection is 
0.5 cm posterior and inferior to the second injection, respectively. This is repeated on the oppo-
site side. As mentioned earlier, additional units can be injected on both or just one side, and 
is based on palpation for significant tenderness and pain that requires additional treatment.
Figure 1. PREEMPT injection protocol. Locations of fixed site, fixed dose injections: (1a) procerus, (1b) corrugators, (1c) 
frontalis, (2) temporalis, (3) occipitalis, (4) cervical paraspinal, and (5) trapezius muscle. Follow-the-pain injection areas 
are indicated in red color.
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5.1.3. Occipital
The occipitalis muscle group is injected with 15 units in three sites on each side, totaling 30 
units. The first injection is 1 cm lateral to and above the occipital protuberance. The second 
injection is given 1 cm lateral and 1 cm above the first injection. Finally, the third injection is 
1 cm medial and 1 cm above the first injection. Similar to the temple area injection, physicians 
can follow the pain by palpating for significant areas of tenderness, and inject additional units.
5.1.4. Cervical spine and paraspinal muscle groups
In the area of the back of the neck, the PREEMPT protocol targets the semispinalis and sple-
nius muscle groups. Injection consists of two sites on each side with 20 units total. On each 
side, the first injection is 3–5 cm inferior and just lateral to the occipital protuberance. Another 
injection is made 1 cm superior and lateral to the first.
5.1.5. Trapezius
The trapezius muscle is injected superiorly into three sites on each side, with 30 units total. 
The fixed dose is 5 units into each of the six total sites. One injection is made into the lateral 
portion of the muscle, another to the middle aspect, and one medially and superior within the 
medial portion of the muscle. With results from palpation for tenderness and pain, the physi-
cian can inject additional sites within the muscle group.
5.2. ART injection technique: Anatomical, Regional, and Targeted [42]
While the PREEMPT trials and its associated injection paradigm have paved the way for the 
development of BTX-A injection in migraine headaches, several other injection techniques 
have been developed, including the Anatomical, Regional, and Targeted (ART) injection 
 paradigm. In contrast to the “fixed site” and “follow the pain” approach of the PREEMPT 
protocol, the ART technique offers a dynamic injection paradigm based on anatomical studies 
and surgical experiences in the decompression of nerves [42].
The ART injection paradigm can be described as Anatomical, Regional, and Targeted [42]. 
In this approach, injection is not necessarily targeted to a broad muscle group. Rather, this 
injection paradigm is designed based more on the direct effects of onabotulinum toxin on 
peripheral nerves, which have been previously described [25, 26, 43, 44]. As a result, injec-
tions rely heavily on accurate understanding of nerve anatomy and delivery of the toxin as 
close to the nerve as possible. The term “Anatomical” refers to injections based on the accurate 
location and depth of a nerve, and its surrounding musculature. “Regional” refers to focused 
injections at regions where pain originates (frontal, temporal, or occipital). “Targeted” refers 
to injections based on the topography of tender areas, which may not always correspond with 
known anatomical compression points. Therefore, the ART injection approach has the poten-
tial to be more individualized to each patient's unique picture of migraine pain.
While the PREEMPT injection paradigm dictates the exact dosage delivered to each site, the 
ART injection protocol is less strict on how much is injected. Previous studies have showed 
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the optimal dosage range per injection cycle is between 150 and 200 units [24]. The standard 
ART dosage consists of 155 units delivered across several sites: 45 units into the frontal site, 
25 units into the temples, 50 units to the GON, 10 units to the LON, 15 units split into the tails 
of the GON and LON, 5 units in the area of the AT nerve, and finally 5 units in the area of the 
tail of the AT nerve. This standard is the injection pattern given to patients who report pain in 
all trigger sites. However, upon physician discretion, more units can be delivered to certain 
areas, or none in certain trigger sites, according to what the patient reports.
5.2.1. Site I: Frontal
In Site I, injection of BTX-A is based on irritation of the supraorbital and supratrochlear 
nerves (SON and STN). In this site, the injection is more anatomical than targeted. If BTX-A 
is injected in areas of maximal tenderness here closer to the orbital rim, the risk for lid ptosis 
and diplopia is high. Therefore, injection is more fixed in this area. The corrugator supercilii 
 muscle (CSM) is thought to compress the SON and STN, but any of the other glabellar muscles 
has the potential to as well (procerus, depressor supercilii). In addition, fibrous bands in the 
supraorbital foramen, or a boney foramen, could also be sources for proximal compression 
and pain. Before injecting into this area, the topographical anatomy of the corrugator muscle 
can be clearly visualized by asking the patient to frown. Of note, studies in plastic surgery lit-
erature have further outlined the anatomy of the corrugator, which is not followed  accurately 
in the PREEMPT/Allergan injection protocol (Figure 2). The CSM begins 3 mm lateral to the 
midline and extends 43 mm laterally. Superiorly, it extends 33 mm from the pupil. An ice 
pack is used to cool the area before injection, as it is important to reduce anxiety and pain in 
the migraine patient. Digital occlusion of the supraorbital and supratrochlear vessels with the 
non-dominant thumb reduces the risk of “microhematomas”. A short 0.5 inch 30-gauge nee-
dle with 0.1 cc graduation is used to inject 12.5 units into each side with a five-point standard 
injection (Figure 3). Based on correct anatomy, injection should be deeper medially and more 
superficial laterally. Single injections can be done on each side using a longer needle inserted 
superficially on the lateral side and extended deeply toward the medial side. Injection should 
be done as the needle is advancing, as it provides for the best control. If bleeding is present, 
gauze can be used, but it is critical not to press with excess pressure as the toxin can diffuse 
into unwanted areas in the upper lid.
Injection into the frontalis muscle should be only in the upper half of the forehead (Figure 3). 
Injecting lower on the forehead leads to a higher rate of lid ptosis. A total of 15–20 units is 
injected. This injection not only targets the distal portions of the SON and STN, but relaxation 
of the frontalis muscle reduces cephalic pull that can cause tension in the proximal nerve areas.
5.2.2. Site II: Temporal
Injection into the temporal area is again more anatomical than targeted. The zygomaticotem-
poral branch of the trigeminal nerve (ZTBTN) emerges approximately 17 mm posterolateral 
and 6.5 mm cephalad to the lateral canthus. This point of exit from the temporalis muscle is 
seen consistently in cadaver studies [45]. A long 30-gauge needle should pierce the temporalis 
muscle 1 cm posterolateral to this point to deposit 12.5 units on each side (Figure 4). The injec-
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tion should be fanned deeply in a 1.5 cm radius. Additionally, a single deep injection at the 
point of nerve exit over the deep temporal fascia should also be performed.
Figure 3. ART frontal trigger site injection. Image demonstrating injection sites over the corrugator muscle. The patient 
frowns to assist in finding the correct locations. The SON and STN nerves are targeted here, as well as the frontalis 
muscle.
Figure 2. The location of the corrugator muscle.
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The auriculotemporal nerve (AT) is another potential source of nerve irritation in the temporal 
area. This nerve is referred to as Site V. Injection at this site is more targeted than anatomical. 
BTX-A delivery should be guided by the patient's descriptions of tender areas, which may not 
always correspond with areas of anatomical compression. Injections should be in two sites: 
one near the proximal AT area where fibrous bands can compress the nerve, and one near the 
distal AT where it crosses the superficial temporal artery [42] (Figure 4).
5.2.3. Site III: Nasoseptal
BTX-A cannot be delivered to this area. A computed tomography scan should be done to 
elucidate areas of turbinate contact or other masses. Currently, the only treatment for this site 
is surgical correction.
5.2.4. Site IV: Occipital
Injection in Site IV is based on irritation of the occipital nerves: greater occipital nerve (GON), 
lesser occipital nerve (LON), and the third occipital nerve (TON). Although the LON can 
be referred to as Site VI, its treatment is considered together with other occipital sites. The 
GON is most commonly the primary site of pain. This injection is both targeted and anatomi-
cal. The nerve consistently pierces the semispinalis capitis muscle at a point 1.5 cm lateral to 
the midline and 3 cm below to the occipital protuberance (Figure 5). However, the area of 
maximal tenderness is often 0.5–1 cm lateral to this point. Therefore, BTX-A injection should 
Figure 4. ART temporal trigger site injections. Figure demonstrating the relationship between the auriculotemporal 
nerve (AT), zygomaticotemporal nerve (ZTBTN), and the superficial temporal artery. It is important to note that the 
ZTBTN is on a different fascial plane, and does not normally contact the AT nerve or temporal artery. Injection sites 
include: (1) 1.5 cm posterolateral emergence of ZTBTN from deep temporal fascia. (2) fascial band compression at 
proximal AT. (3) Distal AT area corresponding to crossing with the superficial temporal artery.
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be targeted to this area. When injecting this nerve, it is critical to inject deeply enough to 
pierce the trapezius fascia, where the nerve resides. A sturdier 27-gauge long needle is used 
to ensure penetration of the thick fascia, with 25 units injected into each side. The LON is 
injected similarly in a targeted and anatomical approach, using 10 units total for both sides 
(Figure 5). The point of maximal tenderness often corresponds anatomically within 0.5 cm of 
the emergence of the LON behind the sternocleidomastoid muscle [46]. The LON emerges 6.4 
cm lateral to the posterior midline drawn through cervical spine, and 7.5 cm caudal from a 
horizontal line drawn between the most superolateral aspects of the external auditory canals 
[47]. Additionally, patients sometimes describe pain in the areas corresponding to the distal 
tails of the GON and LON. In these areas, terminal branches of the occipital artery intertwine 
with the occipital nerves.
Figure 5. ART occipital trigger site injection sites and landmarks. Occipital protuberance (triangle), GON (black oval), 
tail of GON (black square), LON (gray oval), tail of LON (gray square), 3rd occipital nerve (white circle).




OnabotulinumtoxinA injection is an effective strategy to treat chronic migraine. At 56 weeks, 
the percentage of patients in the PREEMPT trials that received at least 50% reduction in head-
ache days was 68%, significantly better than the reduction seen in patients who received 
 placebo [48]. In addition to being effective, BTX-A has also been shown to cause very minimal 
adverse effects. Some commonly seen complications include neck pain/weakness, eyelid ptosis, 
and injection site pain. There have been no reported deaths among migraine BTX-A studies, 
and only 1.4–3.8% of patients discontinued treatment due to adverse effects [9, 10, 16, 17, 24].
BTX-A injection is an effective and well-tolerated treatment option for chronic migraine 
patients who have previously failed a number of traditional medications. It is most effec-
tive in patients who suffer from a higher frequency of headache days, such as those seen in 
chronic migraines. Additionally, it is well known that chronic migraine patients often suffer 
from medication overuse. In a subanalysis of PREEMPT trial results, BTX-A demonstrated 
significant effectiveness in reducing frequency of headache days even in patients who are 
designated with medication overuse [49]. Sometimes, patients may not respond from the 
first injection interval. It has been shown even among patients that fail to respond initially, 
a meaningful proportion of patients responded in the second and third treatment cycles [50]. 
ART injection on the other hand is a newer, expanded, and more refined version of the tar-
geted injection based on recent neurology data and theories suggesting that BTX-A is more 
effective if deposited closer to nerves. Although available studies are less robust, preliminary 
clinical results show less complications than PREEMPT.
While onabotulinumtoxinA injection has been shown to be both safe and effective among a 
broad group of patients, demonstrating versatile and robust efficacy, research is ongoing to 
develop the best and most efficient ways to deliver this treatment. Knowledge of potential 
culprit nerves and the accurate understanding of surrounding tissue anatomy are essential to 
maximize efficacy and efficiency in chronic migraine pain management.
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